MedTrace Logo

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

NCT00319787 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2011-01-25

No results posted yet for this study

Summary

The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.

Conditions

  • Locally Advanced Prostate Cancer

Interventions

DRUG

Iressa

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Norway Medical Director, MD · AstraZeneca AS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2006-08-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319787 on ClinicalTrials.gov